Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Oropharyngeal Neoplasms 1Multiple Myeloma 1Lymphoma 1Hematologic Neoplasms 1Cranial Nerve Diseases 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 7venetoclax 5fludarabine phosphate 5tagraxofusp 3fludarabine 3Whole-Body Irradiation 3Thiotepa 3Mycophenolic Acid 3Methotrexate 3merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Tacrolimus 2Specimen Handling 2Rituximab 2Dexamethasone 2Cytarabine 2Cyclosporins 2Cyclosporine 2Calcium Dobesilate 2prednylidene 1exifone 1deltacortene 1azathiopurine 1X-Rays 1Vincristine 1Sirolimus 1Ranitidine 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blastic Plasmacytoid Dendritic Cell Neoplasm × Medrol Veriderm × 1 year × Clear all
NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡